```
=> d his

     (FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
L1              STRUCTURE UPLOADED
L2            1 S L1
L3           28 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005
L4            3 S L3
L5            1 S L4 AND BURRILL, L?/AU
L6            2 S L4 NOT L5
L7            0 S L6 AND PALMER, J?/AU
L8            1 S L6 AND RYDZEWSKI, R?/AU
L9            1 S L6 NOT L8
L10           3 S BURRILL, L?/AU AND PALMER, J?/AU AND RYDZEWSKI, R?/AU
L11           2 S L10 NOT L4

     FILE 'CAOLD' ENTERED AT 15:58:23 ON 05 DEC 2005

=> s l3
L12           0 L3

=>
```


O
G1
X
1-2
O
Cy
NH
NH
CN
1-2
O


7
26
4
3
5
27
23
2
6
1
6
1-2
12
11
13
10
9
14
16
18
17
1-2
15

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4	OCT 03	MATHDI removed from STN
NEWS 5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8	OCT 27	Free KWIC format extended in full-text databases
NEWS 9	OCT 27	DIOGENES content streamlined
NEWS 10	OCT 27	EPFULL enhanced with additional content
NEWS 11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS 12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13	DEC 05	CASREACT(R) - Over 10 million reactions available

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6

DICTIONARY FILE UPDATES: 4 DEC 2005 HIGHEST RN 869277-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading structure

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

Ak 24X 25
Page 1-A



Page 1-B



Page 2-A



Page 2-B

Page 2-C



Page 3-A



```
Page 3-B
VAR G1=24/25
REP G19=(1-2) 8-1 8-9
REP G20=(1-2) 17-16 17-18
VPA 21-2/3/5/6 S
VPA 22-2/3/5 S
NODE ATTRIBUTES:
HCOUNT  IS M1     AT  10
HCOUNT  IS M1     AT  16
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS C      AT  12
NSPEC   IS C      AT  13
NSPEC   IS C      AT  14
NSPEC   IS C      AT  15
NSPEC   IS C      AT  16
NSPEC   IS RC     AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS C      AT  21
NSPEC   IS C      AT  22
NSPEC   IS C      AT  23
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  8  9 10 11 12 14 15 16 17 18 21 23 24 25
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  25

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 15:54:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       95 TO ITERATE

100.0% PROCESSED       95 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1316 TO     2484
```

```
PROJECTED ANSWERS:                1 TO       80

L2             1 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 160.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:55:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      2222 TO ITERATE

100.0% PROCESSED     2222 ITERATIONS                                28 ANSWERS
SEARCH TIME: 00.00.01

L3             28 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     164.77     164.98

FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 5 Dec 2005  VOL 143 ISS 24
FILE LAST UPDATED: 4 Dec 2005  (20051204/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4             3 L3

=> s l4 and burrill, l?/au
            17 BURRILL, L?/AU
L5              1 L4 AND BURRILL, L?/AU

=> d l5, ibib abs hitstr, 1

L5   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:         2004:267319  HCAPLUS
DOCUMENT NUMBER:          140:304079
TITLE:                    Preparation of iodotyrosine cyanomethylamides as
                          Cathepsin B inhibitors
```

INVENTOR(S): **Burrill, Leland C., II**; Palmer, James T.; Rydzewski, Robert M.
PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026851	A1	20040401	WO 2003-US29545	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498149	AA	20040401	CA 2003-2498149	20030916
EP 1539725	A1	20050615	EP 2003-774482	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-412368P	P	20020920
WO 2003-US29545	W	20030916

OTHER SOURCE(S): MARPAT 140:304079
GI



AB Title compds. [I; R1, R2 = H, alkyl, haloalkyl, hydroxyalkyl, aryl, aralkyl; R1R2 = atoms to form a cycloalkyl, heterocycloalkyl ring; R3 = alkyl, iodo; R4 = (substituted) aryl, heteroaryl, heterocycloalkyl; R5, R6 = H, alkyl], were prepd. as Cathepsin B inhibitors (no data). Thus, 4-morpholinobenzoic acid hydrochloride, hydroxybenzotriazole, Et3N, and EDC were stirred 30 min in DMF; L-3,5-diiodotyrosine, Et3N, and H2O in DMF were added followed by stirring for 16 h to give (S)-3-(4-hydroxy-3,5-diiodophenyl)-2-(4-morpholin-4-ylbenzoylamino)propionic acid. The latter was stirred overnight with aminoacetonitrile hydrochloride, HBTU, and N-methylmorpholine in DMF to give (S)-N-[1-(cyanomethylcarbamoyl)-2-(4-hydroxy-3,5-diiodophenyl)ethyl]-4-morpholin-4-ylbenzamide.

IT **676477-45-5P**, (S)-N-[1-(Cyanomethylcarbamoyl)-2-(4-hydroxy-3,5-diiodophenyl)ethyl]-4-morpholin-4-ylbenzamide **676477-48-8P** **676477-50-2P** **676477-52-4P** **676477-53-5P** **676477-54-6P** **676477-55-7P** **676477-63-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(prepn. of iodotyrosine cyanomethylamides as Cathepsin B inhibitors)

RN 676477-45-5 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-48-8 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-[2-(4-pyridinylamino)-4-thiazolyl]benzoyl]amino]-, (αS)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676477-47-7
CMF C26 H20 I2 N6 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 676477-50-2 HCAPLUS

CN 4-Morpholinecarboxamide, N-[(1S)-2-[(cyanomethyl)amino]-1-[(4-hydroxy-3,5-diiodophenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-52-4 HCAPLUS

CN Benzenepropanamide, N-(1-cyanocyclopropyl)-4-hydroxy-3,5-diiodo-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-53-5 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-3,5-diiodo-4-methoxy-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-54-6 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-55-7 HCAPLUS
CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3-iodo-5-methyl-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-63-7 HCAPLUS
CN Benzenepropanamide, N-(cyanomethyl)-3-ethyl-4-hydroxy-5-iodo-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005)

FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 28 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005
L4 3 S L3

```
L5            1 S L4 AND BURRILL, L?/AU

=> s l4 not l5
L6            2 L4 NOT L5

=> s l6 and palmer, j?/au
          1564 PALMER, J?/AU
L7            0 L6 AND PALMER, J?/AU

=> s l6 and rydzewski, r?/au
            29 RYDZEWSKI, R?/AU
L8            1 L6 AND RYDZEWSKI, R?/AU

=> d l8, ibib abs hitstr, 1

L8   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

ACCESSION NUMBER: 2005:1123751 HCAPLUS
DOCUMENT NUMBER: 143:399840
TITLE: Cathepsin B inhibitors for the treatment of diabetes and metabolic syndrome
INVENTOR(S): Broder, Samuel E.; **Rydzewski, Robert M.**
PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097103	A2	20051020	WO 2005-US11065	20050401

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-558933P P 20040401

AB The invention is directed to the treatment of e.g. Type II diabetes by administering a cathepsin B inhibitor(s).

IT **676477-45-5** **676477-47-7** **676477-53-5**
676477-54-6 **676477-55-7** **676477-63-7**
867030-89-5 **867030-90-8** **867030-91-9**
867030-92-0 **867030-93-1** **867030-94-2**
867030-95-3 **867030-96-4** **867030-97-5**
867030-98-6 **867030-99-7** **867031-00-3**
867031-01-4 **867031-02-5** **867031-03-6**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cathepsin B inhibitors for treatment of diabetes and metabolic syndrome)

RN 676477-45-5 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-47-7 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-[2-(4-pyridinylamino)-4-thiazolyl]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-53-5 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-3,5-diiodo-4-methoxy-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-54-6 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-55-7 HCAPLUS
CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3-iodo-5-methyl-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676477-63-7 HCAPLUS
CN Benzenepropanamide, N-(cyanomethyl)-3-ethyl-4-hydroxy-5-iodo-α-[[4-(4-morpholinyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-89-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 867030-90-8 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[(4-iodobenzoyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-91-9 HCAPLUS

CN Benzenepropanamide, α-[(4-bromobenzoyl)amino]-N-(cyanomethyl)-4-hydroxy-3,5-diiodo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-92-0 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[(4-methylbenzoyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-93-1 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-α-[[4-(1,1-dimethylethyl)benzoyl]amino]-4-hydroxy-3,5-diiodo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-94-2 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(trifluoromethoxy)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-95-3 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(trifluoromethyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-96-4 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(methylthio)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-97-5 HCAPLUS

CN Benzenepropanamide, N-(cyanomethyl)-4-hydroxy-3,5-diiodo-α-[[4-(methylsulfonyl)benzoyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-98-6 HCAPLUS

CN Benzenepropanamide, 3,5-dichloro-α-[(4-chlorobenzoyl)amino]-N-(cyanomethyl)-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867030-99-7 HCAPLUS

CN Benzenepropanamide, α-[(4-bromobenzoyl)amino]-3,5-dichloro-N-(cyanomethyl)-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867031-00-3 HCAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[(1S)-2-[(cyanomethyl)amino]-1-[(3,5-dichloro-4-hydroxyphenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867031-01-4 HCAPLUS

CN Benzenepropanamide, α-[(4-bromobenzoyl)amino]-3,5-dichloro-N-(1-

cyanocyclopropyl)-4-hydroxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 867031-02-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 867031-03-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005)

FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 28 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005

```
L4             3 S L3
L5             1 S L4 AND BURRILL, L?/AU
L6             2 S L4 NOT L5
L7             0 S L6 AND PALMER, J?/AU
L8             1 S L6 AND RYDZEWSKI, R?/AU

=> s l6 not l8
L9             1 L6 NOT L8

=> d l9, ibib abs hitstr, 1

L9   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Other References

ACCESSION NUMBER: 2004:515539 HCAPLUS
DOCUMENT NUMBER: 141:71829
TITLE: Cyanomethyl derivatives as cysteine protease inhibitors
INVENTOR(S): Graupe, Michael; Lau, Agnes J.; Link, John O.; Liu, Yang; Mossman, Craig J.; Patterson, John W.; Zipfel, Sheila M.
PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052921	A1	20040624	WO 2003-US37979	20031126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506114	AA	20040624	CA 2003-2506114	20031126
EP 1569954	A1	20050907	EP 2003-796499	20031126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-431354P P 20021205
WO 2003-US37979 W 20031126
OTHER SOURCE(S): MARPAT 141:71829
GI



AB The dipeptide derivs. [I [R1 = substituted Ph, aryl, diaryl, heterodiaryl, furanyl, arylfuranyl, pyrazolyl, etc.; R2 = H, (un)substituted cycloalkyl, indolyl, alkylindolyl, Me, Et, Pr, pentyl, etc.; R3 = H, or R2 and R3 together with the carbon atom to which they are attached formed (un)substituted cycloalkylene, cycloalkenylene or spirocycloalkylene; R4 = H; R5 = H, (un)substituted alkyl or heteroaryl, or R4 and R5 together with the carbon atom to which they are attached form cycloalkylene or heterocycloalkylene]] were prepd. as cysteine protease inhibitors, in particular, cathepsins B, K, L, F, and S, for treating diseases mediated by these proteases. Thus, compd. II was prepd. via peptide coupling of 2'-chlorobiphenyl-4-carboxylic acid with synthesized 2(S)-amino-N-cyanomethyl-3-(2,6-difluoro-4-methoxyphenyl)-propionamide. Compds. of the invention were tested by in vitro essays for protease activity and showed cathepsins B, K, L, F, and S inhibitory activity.

IT **710350-07-5P 710350-08-6P 710350-37-1P 710350-45-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dipeptide cyanomethyl derivs. as cysteine protease inhibitors)

RN 710350-07-5 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 2'-chloro-N-[(1S)-2-[(cyanomethyl)amino]-1-[(2,6-difluoro-4-methoxyphenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710350-08-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-(2-chlorophenyl)-N-[(1S)-2-[(cyanomethyl)amino]-1-

[(2,6-difluoro-4-methoxyphenyl)methyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710350-37-1 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 6-chloro-4'-[[[(1S)-2-[(cyanomethyl)amino]-1-[(2,6-difluoro-4-methoxyphenyl)methyl]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710350-45-1 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 6-chloro-4'-[[[(1S)-2-[(4-cyano-1-ethyl-4-piperidinyl)amino]-1-[(2,6-difluoro-4-methoxyphenyl)methyl]-2-oxoethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s burrill, l?/au and palmer, j?/au and rydzewski, r?/au
17 BURRILL, L?/AU

```
          1564 PALMER, J?/AU
            29 RYDZEWSKI, R?/AU
L10          3 BURRILL, L?/AU AND PALMER, J?/AU AND RYDZEWSKI, R?/AU

=> d his

     (FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
L1              STRUCTURE UPLOADED
L2            1 S L1
L3           28 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005
L4            3 S L3
L5            1 S L4 AND BURRILL, L?/AU
L6            2 S L4 NOT L5
L7            0 S L6 AND PALMER, J?/AU
L8            1 S L6 AND RYDZEWSKI, R?/AU
L9            1 S L6 NOT L8
L10           3 S BURRILL, L?/AU AND PALMER, J?/AU AND RYDZEWSKI, R?/AU

=> s l10 not l4
L11           2 L10 NOT L4

=> d l11, ibib abs hitstr, 1-2

L11  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2005 ACS on STN
```

Full Text | Citing References

```
ACCESSION NUMBER:        2005:1163295  HCAPLUS
TITLE:                   Design and Synthesis of Tri-Ring P3
                         Benzamide-Containing Aminonitriles as Potent,
                         Selective, Orally Effective Inhibitors of Cathepsin K
AUTHOR(S):               Palmer, James T.; Bryant, Clifford; Wang, Dan-Xiong;
                         Davis, Dana E.; Setti, Eduardo L.; Rydzewski, Robert
                         M.; Venkatraman, Shankar; Tian, Zong-Qiang; Burrill,
                         Leland C.; Mendonca, Rohan V.; Springman, Eric;
                         McCarter, John; Chung, Tobee; Cheung, Harry; Janc,
                         James W.; McGrath, Mary; Somoza, John R.; Enriquez,
                         Philip; Yu, Z. Walter; Strickley, Robert M.; Liu,
                         Liang; Venuti, Michael C.; Percival, M. David;
                         Falgueyret, Jean-Pierre; Prasit, Peppi; Oballa,
                         Renata; Riendeau, Denis; Young, Robert N.; Wesolowski,
                         Gregg; Rodan, Sevgi B.; Johnson, Colena; Kimmel,
                         Donald B.; Rodan, Gideon
CORPORATE SOURCE:        Celera Genomics, Inc., South San Francisco, CA, 94080,
                         USA
SOURCE:                  Journal of Medicinal Chemistry (2005), 48(24),
                         7520-7534
                         CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:               American Chemical Society
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   We have prepd. a series of achiral aminoacetonitriles, bearing tri-ring
     benzamide moieties and an aminocyclohexanecarboxylate residue at P2.  This
     combination of binding elements resulted in sub-250 pM, reversible,
     selective, and orally bioavailable cathepsin K inhibitors.  Lead compds.
     displayed single digit nanomolar inhibition in vitro (of rabbit
     osteoclast-mediated degrdn. of bovine bone).  The best compd. in this
```

series, 39n (CRA-013783/L-006235), was orally bioavailable in rats, with a terminal half-life of over 3 h. 39n was dosed orally in ovariectomized rhesus monkeys once per day for 7 days. Collagen breakdown products were reduced by up to 76% dose-dependently. Plasma concns. of 39n above the bone resorption IC50 after 24 h indicated a correlation between functional cellular and in vivo assays. Inhibition of collagen breakdown by cathepsin K inhibitors suggests this mechanism of action may be useful in osteoporosis and other indications involving bone resorption.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

Full Text | Citing References

ACCESSION NUMBER: 2004:143127 HCAPLUS
DOCUMENT NUMBER: 140:193099
TITLE: Heterocyclic compound proteasome inhibitors, pharmaceutical compositions, and therapeutic use
INVENTOR(S): **Burrill, Leland C., III**; Mendonca, Rohan V.; **Palmer, James T.**; **Rydzewski, Robert M.**
PATENT ASSIGNEE(S): Axys Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014882	A2	20040219	WO 2003-US24960	20030808
WO 2004014882	A3	20040805		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-402183P P 20020809
OTHER SOURCE(S): MARPAT 140:193099

AB The invention discloses heterocyclic compds. that are proteasome inhibitors, pharmaceutical compns. comprising such compds., and methods of treating diseases mediated by unregulated proteasome activity. Compd. prepn. is included.

=> d his

(FILE 'HOME' ENTERED AT 15:49:28 ON 05 DEC 2005)

FILE 'REGISTRY' ENTERED AT 15:49:34 ON 05 DEC 2005
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 28 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 05 DEC 2005

```
L4              3 S L3
L5              1 S L4 AND BURRILL, L?/AU
L6              2 S L4 NOT L5
L7              0 S L6 AND PALMER, J?/AU
L8              1 S L6 AND RYDZEWSKI, R?/AU
L9              1 S L6 NOT L8
L10             3 S BURRILL, L?/AU AND PALMER, J?/AU AND RYDZEWSKI, R?/AU
L11             2 S L10 NOT L4

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    34.82     199.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.65      -3.65

FILE 'CAOLD' ENTERED AT 15:58:23 ON 05 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file supports REGistRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
```